News and Announcements
Proteomics International Laboratories Signs Largest Analytics Contract to Date & Becomes the World’s Most Accredited Protein Testing Lab
- Published August 11, 2017 12:00AM UTC
- Publisher Wholesale Investor
- Categories Company Updates
Medical technology company Proteomics International Laboratories Ltd (ASX: PIQ) is pleased to provide the following update on its business activities for the three-month period to 30 June 2017.
KEY TAKEAWAYS:
- Validation study confirms PromarkerD can predict diabetic kidney disease better than any current measure.
- Results of the validation study were presented to world’s largest gathering of diabetes experts at the American Diabetes Association’s 77th Annual Scientific Sessions.
- New potential income stream through analytical services for clinical trials.
- Proteomics International became the world’s most accredited protein testing laboratory, and launched pharmacokinetic and companion diagnostic testing for clinical trials.
- Largest analytics contract to date (worth A$200,000) was signed, and year on year income growth is 28%. PIQ is aiming for its operations to be cashflow break even by the end of the 2017/18 financial year.
Company Updates
The Algorithm Re-Dosing Cancer Treatment: Inside the University of Melbourne Spin-Out Rewriting a 60-Year-Old Formula
Oncology specialists are still calculating toxic chemotherapy doses using a formula from the era of the Ford Model T, leading to a system where seven out of eight patients are routinely overdosed. University of Melbourne spin-out PredicTx is dismantling this legacy approach, utilizing advanced AI to analyze existing patient CT scans, deliver precision medicine to the bedside, and return a massive 100x financial rerate to hospital networks.
Asset over thematic: Centuria’s Andrew Essey warns against ‘blanket strategies’ as global capital eyes Australia
Relying solely on broad macroeconomic trends is the single biggest mistake property investors make today. Centuria Capital CIO Andrew Essey explains why asset-level “lettability” always trumps the overarching sector thematic, and reveals where global institutional capital is quietly pivoting to capture high-octane returns.
Material gains: Swinburne spin-out EntroMat takes aim at $160b global market
Traditional metallurgy has hit a performance wall. Discover how Swinburne University spin-out EntroMat is leveraging physics-based AI and circular critical minerals to engineer high-entropy alloys capable of surviving the world’s most extreme industrial environments.
Backed By Leading Investment Groups and Family Offices
